Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Immune Thrombocytopenic Purpura: New Biological Therapy of an Old Disease

Author(s): Melda Comert Ozkan, Fahri Sahin and Guray Saydam

Volume 22, Issue 16, 2015

Page: [1956 - 1962] Pages: 7

DOI: 10.2174/0929867322666150319102830

Price: $65

Abstract

Immune Thrombocytopenic Purpura (ITP) is the most common autoimmune disorder that is caused by antibody- mediated destruction of thrombocytes and impaired megakaryocyte platelet production. ITP remains a diagnosis of exclusion. Recent pathophysiologic mechanisms and therapeutical approaches of ITP have emerged. Although steroids and intravenous immunglobulins (IVIg) have still been the main therapeutic strategies, a group of patients develop resistance to those eventually and there have been some biological treatment options such as rituximab especially in the last decade. In this review article, we have summarized the therapeutic options for patients with ITP and mainly focused on the timing and potential effects of biological agents.

Keywords: Autoimmune disorders, biological therapy, immune thrombocytopenic purpura, rituximab.


Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy